Business Standard

Sun Pharma's growth pill: Specialising in specialty and scaling in India

Brokerages administer confidence boost, elevating EPS forecasts and target prices for 2024-25

Sun Pharma
Premium

Sun Pharma

Ram Prasad Sahu Mumbai

Listen to This Article

Traction for its specialty portfolio, a strong showing in the domestic market, and better regulatory compliance are positives for the country’s largest pharmaceutical (pharma) company, Sun Pharmaceutical Industries.

Given the triggers, some brokerages have increased their earnings per share estimates and target price for 2024–25 (FY25). This should sustain the momentum for the stock, which has been one of the major pharma gainers in 2023–24 (FY24), rising 57 per cent. It is currently trading at Rs 1,547 per share.

Although the base for its specialty segment is high, brokerages expect the company to sustain growth rates.

ALSO READ: 

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in